Please assess the completion status of the following clinical trial:

Trial Title: Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Prader Willi Syndrome confirmed by genetic testing (DNA methylation or FISH)~* Ages 13-20 years~* body mass index (BMI) \> 85th percentile for age and gender~Exclusion Criteria:~* Is currently using or has previously used a glucagon-like peptide-1 (GLP-1) agonist~* History of pancreatitis, or renal failure~* History of familial pancreatitis~* Amylase, or lipase levels \> 2.5 times the upper limit of normal any time in the previous 2 years~* Creatinine clearance \< 30 mL/min~* Other syndromic diagnoses~* gastrointestinal (GI) or renal illness in the 1 month prior to entering study~* Inability to take study drug~* Pregnancy~* Initiation of growth hormone (GH), estrogen, or testosterone or change \> 25% of dose/kg/day during the 6 months prior to starting study~* Non-English speaking

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: EXPERIMENTAL): All subjects enrolled in this study will be given Exenatide for 6 months. Exenatide: The investigators will give patients naive to GLP-1 agonists exenatide per manufacturer dosing recommendations for 6 months. The investigators will begin by giving 5 mcg subcutaneously twice a day for 1 month and then increase the dose to 10 mcg subcutaneously twice a day for the remainder of the study (5 months).

Based on this trial design, predict the completion outcome and termination type (if applicable).